Institutional members access full text with Ovid®

Share this article on:

Easy-to-Use Online Software Package for Internal Dose Assessment After Radionuclide Treatment in Clinical Routine

Mirzaei, Siroos MD*; Sohlberg, Antti PhD; Knoll, Peter PhD*; Zakavi, Rasoul MD; Diemling, Markus PhD§

doi: 10.1097/RLU.0b013e31828da3db
Original Articles

Background Internal dose assessment after radionuclide therapy is usually performed using home-made software packages. The dose assessment includes image registration, region-of-interest drawing, time-activity curve generation, and manual calculation of residence times followed by dose calculation with the OLINDA/MIRD software. The drawback of these methods is that several steps have to be performed using various software products possibly installed on different workstations. The aforementioned approaches are error-prone as well as difficult and time-consuming. In this article, we present a commercial software package that implements all the required dose calculation steps in 1 application, which greatly facilitates the internal dose assessment.

Methods and Results The workflow of the newly developed software package “Hybrid Dosimetry” proceeds from automatic image registration to region-of-interest drawing, followed by time-activity curve fitting and dose calculation according to the MIRD method. The software is available online and can be run on independent computers using images in the common DICOM format. We used the package for internal dosimetry of 8 patients treated with 177Lu-DOTATATE and compared the results with manual dose calculation.

Conclusions The online software package presented is platform independent and allows fast dose calculations. The results obtained with the new package were in perfect agreement with manual methods.

From the *Department of Nuclear Medicine With PET Center, Wilhelminenspital, Vienna, Austria; †Laboratory of Clinical Physiology and Nuclear Medicine, Joint Authority for Päijät-Häme Social and Health Care, Lahti, Finland; ‡Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; and §Hermes Medical Solutions Ltd, London, United Kingdom.

Received for publication November 20, 2012; revision accepted January 14, 2013.

Conflicts of interest and sources of funding: The “Hybrid Dosimetry” was provided without charges from “Hermes Medical Solutions” to the Department of Nuclear Medicine at Wilhelminenspital.

Reprints: Siroos Mirzaei, MD, Wilhelminenspital, Institute of Nuclear Medicine with PET Center, Montleartstr 37, A-1160 Vienna, Austria. E-mail:

© 2013 by Lippincott Williams & Wilkins